Cointime

Download App
iOS & Android

Sam Bankman-Fried needs more Adderall to focus during trial, say lawyers

Validated Media

FTX co-founder Sam Bankman-Fried has asked a United States judge for long-release Adderall, saying he’s finding it hard to concentrate properly during his criminal trial.

In an Oct. 15 letter to New York District Judge Lewis Kaplan, Bankman-Fried’s lawyers asked if Bankman-Fried could take a “12-hour extended-release 20mg dose of Adderall” before he’s transported to trial on Oct. 16.

The lawyers added that Bankman-Fried’s lack of the prescribed stimulant during trial hours means he’s “not been able to concentrate at the level he ordinarily would.”

As Bankman-Fried’s defense case and the decision on whether he will testify approaches, his lawyers are concerned the FTX founder won’t be able to “meaningfully participate” in presenting his defense without medication.

Highlighted excerpt of the letter to Judge Kaplan explaining Bankman-Fried's need for his prescription medication. Source: CourtListener

The former FTX CEO has been “doing his best to remain focused during the trial” despite his lack of medication during trial hours, the letter added.

Even if Bankman-Fried takes the requested medication, there’s “no way of knowing at present whether the extended-release dose will be effective,” his lawyers claimed.

They requested the court stop the trial for one day — on Tuesday, Oct. 17 — if Bankman-Fried could not take the long-release dose or if the medication didn’t work so they could “find a solution that will work for the remainder of [the] trial.”

Alternatively, the lawyers requested that Judge Kaplan permit them to provide Bankman-Fried with his prescription of Adderall at the District Court during the trial.

The lawyers claimed they had attempted to solve the issue with the Bureau of Prisons, but had not received a response to their five attempts to contact the BOP via email and calls between Oct. 5 and Oct. 12.

Judge Kaplan first approved a motion allowing Bankman-Fried to access Adderall and anti-depressant medication while in prison on Aug. 14 after his lawyers said he has a history of Major Depressive Disorder and Attention Deficit Hyperactivity Disorder (ADHD) and has been under psychiatric care since early 2019.

Shortly after the approval, Bankman-Fried’s lawyers complained about his lack of access to medication, saying in an Aug. 22 hearing that he had not received Adderall for the previous 11 days.

Bankman-Fried’s criminal trial is entering its third week, previously, the court heard testimony from Alameda Research former CEO and Bankman-Fried’s ex-girlfriend Caroline Ellison, FTX co-founder Gary Wang and a former developer for FTX, Adam Yedidia.

Bankman Fried has pleaded not guilty and maintained his innocence during the trial.

Comments

All Comments

Recommended for you

  • BTC Surpasses $82,000

    Market data shows that BTC has surpassed $82,000, currently priced at $82,038.65, with a 24-hour increase of 0.31%. The market is experiencing significant volatility, so please ensure proper risk management.

  • ETH Surpasses $2400

    Market data shows that ETH has surpassed $2400, currently priced at $2400.26, with a 24-hour decline of 1.33%. The market is experiencing significant volatility, so please ensure proper risk management.

  • BTC Surpasses $81,000

    Market data shows that BTC has surpassed $81,000, currently priced at $81,016.34, with a 24-hour decline of 1.53%. The market is experiencing significant volatility, so please ensure proper risk management.

  • BTC Falls Below $80,000

    Market data shows that BTC has fallen below $80,000, currently priced at $79,940.09, with a 24-hour decline of 3.44%. The market is experiencing significant volatility, so please ensure proper risk management.

  • Philadelphia Semiconductor Index Set to Lose Over $2 Trillion in Market Value in Seven Trading Days

    The Philadelphia Semiconductor Index is poised to evaporate over $2 trillion in market value within seven trading days.

  • Philadelphia Semiconductor Index Drops 4% to Lowest Level in Nearly a Month

    The Philadelphia Semiconductor Index fell by 4.01% during the day, currently reported at 11,215.37 points. Nvidia dropped by 3.25%, Broadcom fell by 2.87%, Micron decreased by 5.79%, Intel declined by 5.81%, AMD dropped by 6.28%, Qualcomm rose by 0.66%, TSMC fell by 4.37%, and ASML decreased by 3.34%.

  • Philadelphia Semiconductor Index Falls 4% to Lowest Level in Nearly a Month

    The Philadelphia Semiconductor Index dropped 4.01% during the day, currently reported at 11,215.37 points. Nvidia fell by 3.25%, Broadcom by 2.87%, Micron by 5.79%, Intel by 5.81%, AMD by 6.28%, Qualcomm rose by 0.66%, TSMC fell by 4.37%, and ASML dropped by 3.34%.

  • Ripple Prime Launches Perpetual Contract Trading Services for Institutional Clients

    According to Bloomberg, Ripple's main brokerage division, Ripple Prime, is launching perpetual contracts for real-world assets (RWA) aimed at institutional clients, covering over 100 reference markets including stocks, indices, ETFs, and commodities. This product is offered through Trade.xyz on Hyperliquid, continuing Ripple Prime's previous initiative to provide clients with access to cryptocurrency perpetual contract trading.

  • NYC Comptroller Urges Anthropic to Pause IPO Plans

    On October 15, New York City Comptroller Mark Levine stated in an interview that he has written to Anthropic CEO Dario Amodei, urging the company to suspend its planned initial public offering (IPO). In the letter, he called for Anthropic to pause its IPO plans until it can fully and transparently address concerns related to AI safety, governance, and development that the company itself has raised. Levine wrote that the company should focus on mitigating these risks rather than advancing the IPO. Currently, New York City has an investment exposure of less than $10 million in Anthropic through the private market.

  • US September PPI Rises 6.3% Year-on-Year, Exceeding Market Expectations

    The US Producer Price Index (PPI) for September recorded a year-on-year increase of 6.3%, the highest since May 2026, surpassing market expectations of 5.3%. The month-on-month PPI for September was reported at 1.3%, significantly higher than the market forecast of 0.5%. Additionally, US retail sales for September showed a month-on-month increase of 0.8%, also exceeding market expectations.